Martin Benesch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Martin Benesch has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Christian Urban
Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Division of Pediatric Hematology/Oncology, Graz, Austria
6 shared publications - Herwig Lackner
Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Division of Pediatric Hematology/Oncology, Graz, Austria
6 shared publications - Wolfgang Schwinger
Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Division of Pediatric Hematology/Oncology, Graz, Austria
5 shared publications - Petra Sovinz
Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, 8036 Graz, Austria
3 shared publications - Andrea Raicht
Department of Paediatrics and Adolescent Medicine, Division of Paediatric Haematology and Oncology, Medical University Graz, Auenbruggerplatz 38, 8036 Graz, Austria
2 shared publications - Anna Maria Birkl-Toeglhofer
Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria
2 shared publications
Latest Publications
- Open Access
Prognostic Impact of Pulmonary Metastasectomy in Bone Sarcoma Patients: A Retrospective, Single-Centre Study
This retrospective study aimed at analyzing the impact of metastasectomy on post-metastasis survival (PMS) in bone sarcoma patients with lung metastases. Altogether, 47 bone sarcoma patients (24 males, median age at diagnosis of lung metastases: 21.8 (IQR: 15.6–47.3) years) with primary (n = 8) or secondary (n = 39) lung metastases treated at a single university hospital were retrospectively included. Based on a propensity score, inverse probability of treatment weight (IPTW) was calculated to account for selection bias whether patients had undergone metastasectomy or not. The most common underlying histology was osteosarcoma (n = 37; 78.7%). Metastasectomy was performed in 39 patients (83.0%). Younger patients (p = 0.025) with singular (p = 0.043) and unilateral lesions (p = 0.024), as well as those with an interval ≥ 9 months from primary diagnosis to development of lung metastases (p = 0.024) were more likely to undergo metastasectomy. Weighted 1- and 3-year PMS after metastasectomy was 80.8% and 58.3%, compared to 88.5% and 9.1% for patients who did not undergo metastasectomy. Naive Cox-regression analysis demonstrated a significantly prolonged PMS for patients with metastasectomy (HR: 0.142; 95%CI: 0.045–0.450; p = 0.001), which was confirmed after IPTW-weighting (HR: 0.279; 95%CI: 0.118–0.662; p = 0.004), irrespective of age, time to metastasis, and the number of lesions. In conclusion, metastasectomy should be considered in bone sarcoma patients with lung metastases, after carefully considering the individual risks, to possibly improve PMS.
Open AccessPrognostic Impact of Pulmonary Metastasectomy in Bone Sarcoma Patients: A Retrospective, Single-Centre Study
This retrospective study aimed at analyzing the impact of metastasectomy on post-metastasis survival (PMS) in bone sarcoma patients with lung metastases. Altogether, 47 bone sarcoma patients (24 males, median age at diagnosis of lung metastases: 21.8 (IQR: 15.6–47.3) years) with primary (n = 8) or secondary (n = 39) lung metastases treated at a single university hospital were retrospectively included. Based on a propensity score, inverse probability of treatment weight (IPTW) was calculated to account for selection bias whether patients had undergone metastasectomy or not. The most common underlying histology was osteosarcoma (n = 37; 78.7%). Metastasectomy was performed in 39 patients (83.0%). Younger patients (p = 0.025) with singular (p = 0.043) and unilateral lesions (p = 0.024), as well as those with an interval ≥ 9 months from primary diagnosis to development of lung metastases (p = 0.024) were more likely to undergo metastasectomy. Weighted 1- and 3-year PMS after metastasectomy was 80.8% and 58.3%, compared to 88.5% and 9.1% for patients who did not undergo metastasectomy. Naive Cox-regression analysis demonstrated a significantly prolonged PMS for patients with metastasectomy (HR: 0.142; 95%CI: 0.045–0.450; p = 0.001), which was confirmed after IPTW-weighting (HR: 0.279; 95%CI: 0.118–0.662; p = 0.004), irrespective of age, time to metastasis, and the number of lesions. In conclusion, metastasectomy should be considered in bone sarcoma patients with lung metastases, after carefully considering the individual risks, to possibly improve PMS.
- 24 April 2022
- Published by Springer Nature
- p. 249-252
Gastrointestinal Stromal Tumors in Children and Adolescents
- 24 April 2022
- Published by Springer Nature
- p. 249-252
Gastrointestinal Stromal Tumors in Children and Adolescents
- Open Access
A Profound Basic Characterization of eIFs in Gliomas: Identifying eIF3I and 4H as Potential Novel Target Candidates in Glioma Therapy
Glioblastoma (GBM) is an utterly devastating cerebral neoplasm and current therapies only marginally improve patients’ overall survival (OS). The PI3K/AKT/mTOR pathway participates in gliomagenesis through regulation of cell growth and proliferation. Since it is an upstream regulator of the rate-limiting translation initiation step of protein synthesis, controlled by eukaryotic initiation factors (eIFs), we aimed for a profound basic characterization of 17 eIFs to identify potential novel therapeutic targets for gliomas. Therefore, we retrospectively analyzed expressions of mTOR-related proteins and eIFs in human astrocytoma samples (WHO grades I–IV) and compared them to non-neoplastic cortical control brain tissue (CCBT) using immunoblot analyses and immunohistochemistry. We examined mRNA expression using qRT-PCR and additionally performed in silico analyses to observe the influence of eIFs on patients’ survival. Protein and mRNA expressions of eIF3B, eIF3I, eIF4A1, eIF4H, eIF5 and eIF6 were significantly increased in high grade gliomas compared to CCBT and partially in low grade gliomas. However, short OS was only associated with high eIF3I gene expression in low grade gliomas, but not in GBM. In GBM, high eIF4H gene expression significantly correlated with shorter patient survival. In conclusion, we identified eIF3I and eIF4H as the most promising targets for future therapy for glioma patients.
Open AccessA Profound Basic Characterization of eIFs in Gliomas: Identifying eIF3I and 4H as Potential Novel Target Candidates in Glioma Therapy
Glioblastoma (GBM) is an utterly devastating cerebral neoplasm and current therapies only marginally improve patients’ overall survival (OS). The PI3K/AKT/mTOR pathway participates in gliomagenesis through regulation of cell growth and proliferation. Since it is an upstream regulator of the rate-limiting translation initiation step of protein synthesis, controlled by eukaryotic initiation factors (eIFs), we aimed for a profound basic characterization of 17 eIFs to identify potential novel therapeutic targets for gliomas. Therefore, we retrospectively analyzed expressions of mTOR-related proteins and eIFs in human astrocytoma samples (WHO grades I–IV) and compared them to non-neoplastic cortical control brain tissue (CCBT) using immunoblot analyses and immunohistochemistry. We examined mRNA expression using qRT-PCR and additionally performed in silico analyses to observe the influence of eIFs on patients’ survival. Protein and mRNA expressions of eIF3B, eIF3I, eIF4A1, eIF4H, eIF5 and eIF6 were significantly increased in high grade gliomas compared to CCBT and partially in low grade gliomas. However, short OS was only associated with high eIF3I gene expression in low grade gliomas, but not in GBM. In GBM, high eIF4H gene expression significantly correlated with shorter patient survival. In conclusion, we identified eIF3I and eIF4H as the most promising targets for future therapy for glioma patients.
- Open Access
Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma
Neuroblastoma (NB) is the most common extracranial pediatric solid tumor. Children suffering from high-risk and/or metastatic NB often show no response to therapy, and new therapeutic approaches are urgently needed. Malignant tumor development has been shown to be driven by the dysregulation of eukaryotic initiation factors (eIFs) at the translation initiation. Especially the activity of the heterotrimeric eIF4F complex is often altered in malignant cells, since it is the direct connection to key oncogenic signaling pathways such as the PI3K/AKT/mTOR-pathway. A large body of literature exists that demonstrates targeting the translational machinery as a promising anti-neoplastic approach. The objective of this study was to determine whether eIF4F complex members are aberrantly expressed in NB and whether targeting parts of the complex may be a therapeutic strategy against NB. We show that eIF4AI is overexpressed in NB patient tissue using immunohistochemistry, immunoblotting, and RT-qPCR. NB cell lines exhibit decreased viability, increased apoptosis rates as well as changes in cell cycle distribution when treated with the synthetic rocaglate CR-1-31-B, which clamps eIF4A and eIF4F onto mRNA, resulting in a translational block. Additionally, this study reveals that CR-1-31-B is effective against NB cell lines at low nanomolar doses (≤20 nM), which have been shown to not affect non-malignant cells in previous studies. Thus, our study provides information of the expression status on eIF4AI in NB and offers initial promising insight into targeting translation initiation as an anti-tumorigenic approach for NB.
Open AccessEukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma
Neuroblastoma (NB) is the most common extracranial pediatric solid tumor. Children suffering from high-risk and/or metastatic NB often show no response to therapy, and new therapeutic approaches are urgently needed. Malignant tumor development has been shown to be driven by the dysregulation of eukaryotic initiation factors (eIFs) at the translation initiation. Especially the activity of the heterotrimeric eIF4F complex is often altered in malignant cells, since it is the direct connection to key oncogenic signaling pathways such as the PI3K/AKT/mTOR-pathway. A large body of literature exists that demonstrates targeting the translational machinery as a promising anti-neoplastic approach. The objective of this study was to determine whether eIF4F complex members are aberrantly expressed in NB and whether targeting parts of the complex may be a therapeutic strategy against NB. We show that eIF4AI is overexpressed in NB patient tissue using immunohistochemistry, immunoblotting, and RT-qPCR. NB cell lines exhibit decreased viability, increased apoptosis rates as well as changes in cell cycle distribution when treated with the synthetic rocaglate CR-1-31-B, which clamps eIF4A and eIF4F onto mRNA, resulting in a translational block. Additionally, this study reveals that CR-1-31-B is effective against NB cell lines at low nanomolar doses (≤20 nM), which have been shown to not affect non-malignant cells in previous studies. Thus, our study provides information of the expression status on eIF4AI in NB and offers initial promising insight into targeting translation initiation as an anti-tumorigenic approach for NB.
- Open Access
- 9 January 2020
- Published by Springer Nature in Pädiatrie & Pädologie
- Vol. 55 (1) , 21-27
Medikamentöse Therapie vaskulärer Anomalien
Zusammenfassung: Vaskuläre Anomalien werden nach der Klassifikation der International Society for the Study of Vascular Anomalies in vaskuläre Tumoren, die als häufigste Entitäten kaposiforme Hämangioendotheliome und Hämangiome umfassen, und vaskuläre Malformationen unterteilt. Die Behandlung vaskulärer Anomalien erfolgt interdisziplinär und basiert, abhängig von der Entität auf Resektion, Sklero‑/Kryotherapie, Embolisation und medikamentöser (antiangiogenetischer und/oder zytostatischer) Therapie. Eine komplette Entfernung ist aufgrund von Ausdehnung und meist diffus infiltrativem Wachstum nur in sehr wenigen Fällen möglich. Seit der Erstbeschreibung der Wirksamkeit in dieser Indikation 2008 gilt Propranolol als etablierte Erstlinienbehandlung für komplizierte infantile Hämangiome. Sirolimus ist ein in der Organtransplantation verbreitet eingesetztes Immunsuppressivum, das den Mammalian/mechanistic-target-of-rapamycin(mTOR)-Signalübertragungsweg inhibiert, auch antiangiogenetisch wirksam ist und daher zunehmend für die Behandlung von vaskulären Tumoren und Malformationen eingesetzt wird. Drei Säuglinge mit vaskulären Anomalien (kaposiformes Hämangioendotheliom, gemischt makro‑/mikrozystische lymphatische Malformation, diffuses infantiles Leberhämangiom) erhielten eine Propranolol‑/Sirolimus-basierte medikamentöse Therapie, ohne klinisch relevante Nebenwirkungen entwickelt zu haben. Obwohl die Verträglichkeit von Propranolol und Sirolimus meist ausgezeichnet ist, erfordern schwere, mitunter lebensbedrohliche Nebenwirkungen (Propranolol: kardiovaskulär; Sirolimus: infektiös), die in Einzelfällen berichtet sind, besondere Beachtung.
- 9 January 2020
- Published by Springer Nature in Pädiatrie & Pädologie
- Vol. 55 (1) , 21-27
Open AccessMedikamentöse Therapie vaskulärer Anomalien
Zusammenfassung: Vaskuläre Anomalien werden nach der Klassifikation der International Society for the Study of Vascular Anomalies in vaskuläre Tumoren, die als häufigste Entitäten kaposiforme Hämangioendotheliome und Hämangiome umfassen, und vaskuläre Malformationen unterteilt. Die Behandlung vaskulärer Anomalien erfolgt interdisziplinär und basiert, abhängig von der Entität auf Resektion, Sklero‑/Kryotherapie, Embolisation und medikamentöser (antiangiogenetischer und/oder zytostatischer) Therapie. Eine komplette Entfernung ist aufgrund von Ausdehnung und meist diffus infiltrativem Wachstum nur in sehr wenigen Fällen möglich. Seit der Erstbeschreibung der Wirksamkeit in dieser Indikation 2008 gilt Propranolol als etablierte Erstlinienbehandlung für komplizierte infantile Hämangiome. Sirolimus ist ein in der Organtransplantation verbreitet eingesetztes Immunsuppressivum, das den Mammalian/mechanistic-target-of-rapamycin(mTOR)-Signalübertragungsweg inhibiert, auch antiangiogenetisch wirksam ist und daher zunehmend für die Behandlung von vaskulären Tumoren und Malformationen eingesetzt wird. Drei Säuglinge mit vaskulären Anomalien (kaposiformes Hämangioendotheliom, gemischt makro‑/mikrozystische lymphatische Malformation, diffuses infantiles Leberhämangiom) erhielten eine Propranolol‑/Sirolimus-basierte medikamentöse Therapie, ohne klinisch relevante Nebenwirkungen entwickelt zu haben. Obwohl die Verträglichkeit von Propranolol und Sirolimus meist ausgezeichnet ist, erfordern schwere, mitunter lebensbedrohliche Nebenwirkungen (Propranolol: kardiovaskulär; Sirolimus: infektiös), die in Einzelfällen berichtet sind, besondere Beachtung.
- Top Cited Papers
- 4 June 2015
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (12) , 1579-1584
Sirolimus for the treatment of children with various complicated vascular anomalies
Vascular anomalies include a heterogeneous group of disorders that are categorized as vascular tumors or vascular malformations. Treatment options include resection, embolization, laser therapy, and sclerotherapy or medical treatment such as propranolol, steroids, interferon, and cytostatic chemotherapy. Mammalian target of rapamycin seems to play a key role in the signal pathway of angiogenesis and subsequently in the development of vascular anomalies. Recently, the successful use of sirolimus has been reported in children with lymphatic malformations and kaposiform hemangioendotheliomas. We report on six patients with different vascular anomalies (kaposiform hemangioendothelioma n = 2, combined lymphatico-venous malformation n = 2, pulmonary lymphangiectasia n = 1, and orbital lymphatic malformation n = 1) who were treated with peroral sirolimus. Three of the children initially presented with a Kasabach-Merrit phenomenon. Median duration of treatment was 10 months; two children are still on treatment. Three children each achieved complete and partial remission. Kasabach-Merrit phenomenon resolved within 1 month in all patients. Treatment with sirolimus was tolerated well; only mild reversible leukopenia was observed. Conclusion: Sirolimus proved to be effective in children with complicated lymphatic or lymphatico-venous malformations and kaposiform hemangioendotheliomas. Treatment was tolerated well with acceptable side effects. The optimum length of treatment and possible long-term side effects have to be evaluated. What is Known: • Vascular anomalies including vascular tumors and vascular malformations may lead to life-threatening conditions. • Some patients are refractory to established treatment and/or are not available for local invasive procedures. What is New: • We reviewed the literature focusing treatment of vascular anomalies in children and adolescents. • Our data support recent studies that sirolimus is an effective treatment option in patients with complicated vascular tumors and malformations. What is Known: • Vascular anomalies including vascular tumors and vascular malformations may lead to life-threatening conditions. • Some patients are refractory to established treatment and/or are not available for local invasive procedures. What is New: • We reviewed the literature focusing treatment of vascular anomalies in children and adolescents. • Our data support recent studies that sirolimus is an effective treatment option in patients with complicated vascular tumors and malformations.
- 4 June 2015
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (12) , 1579-1584
Top Cited PapersSirolimus for the treatment of children with various complicated vascular anomalies
Vascular anomalies include a heterogeneous group of disorders that are categorized as vascular tumors or vascular malformations. Treatment options include resection, embolization, laser therapy, and sclerotherapy or medical treatment such as propranolol, steroids, interferon, and cytostatic chemotherapy. Mammalian target of rapamycin seems to play a key role in the signal pathway of angiogenesis and subsequently in the development of vascular anomalies. Recently, the successful use of sirolimus has been reported in children with lymphatic malformations and kaposiform hemangioendotheliomas. We report on six patients with different vascular anomalies (kaposiform hemangioendothelioma n = 2, combined lymphatico-venous malformation n = 2, pulmonary lymphangiectasia n = 1, and orbital lymphatic malformation n = 1) who were treated with peroral sirolimus. Three of the children initially presented with a Kasabach-Merrit phenomenon. Median duration of treatment was 10 months; two children are still on treatment. Three children each achieved complete and partial remission. Kasabach-Merrit phenomenon resolved within 1 month in all patients. Treatment with sirolimus was tolerated well; only mild reversible leukopenia was observed. Conclusion: Sirolimus proved to be effective in children with complicated lymphatic or lymphatico-venous malformations and kaposiform hemangioendotheliomas. Treatment was tolerated well with acceptable side effects. The optimum length of treatment and possible long-term side effects have to be evaluated. What is Known: • Vascular anomalies including vascular tumors and vascular malformations may lead to life-threatening conditions. • Some patients are refractory to established treatment and/or are not available for local invasive procedures. What is New: • We reviewed the literature focusing treatment of vascular anomalies in children and adolescents. • Our data support recent studies that sirolimus is an effective treatment option in patients with complicated vascular tumors and malformations. What is Known: • Vascular anomalies including vascular tumors and vascular malformations may lead to life-threatening conditions. • Some patients are refractory to established treatment and/or are not available for local invasive procedures. What is New: • We reviewed the literature focusing treatment of vascular anomalies in children and adolescents. • Our data support recent studies that sirolimus is an effective treatment option in patients with complicated vascular tumors and malformations.
- 12 August 2014
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 31 (8) , 723-730
Unrelated CD3/CD19-Depleted Peripheral Stem Cell Transplantation for Hurler Syndrome
For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice. One boy and one girl aged 20.5 and 22 months, respectively, with MPS1-H received a conditioning regimen consisting of thiotepa, fludarabine, treosulfan, and ATG. Grafts were peripheral blood stem cells from unrelated donors (10/12 and 11/11 matched), that were manipulated by CD3/CD19 depletion and contained 20.3 and 28.2 × 10(6) CD34+ cells/kg body weight, respectively. Both patients achieved stable hematopoietic engraftment and stable donor chimerism. Neither acute or chronic graft-versus-host disease (GVHD) nor other severe transplant-related complications occurred. At a follow-up of 48 and 37 months, both patients are alive and well with normal levels of α-L-iduronidase and have made major neurodevelopmental progress. Treosulfan-based conditioning offers the advantage of reduced toxicity; the use of unrelated CD3/CD19-depleted peripheral stem cell grafts allows transfusion of high CD34+ cell numbers together with a "tailored" number of CD3+ cells as well as engraftment facilitating cells in order to achieve rapid hematopoietic engraftment while reducing the risk of graft rejection and GVHD. This regimen might be an additional option when unrelated donor HSCT is considered for a patient with MPS1-H
- 12 August 2014
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 31 (8) , 723-730
Unrelated CD3/CD19-Depleted Peripheral Stem Cell Transplantation for Hurler Syndrome
For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice. One boy and one girl aged 20.5 and 22 months, respectively, with MPS1-H received a conditioning regimen consisting of thiotepa, fludarabine, treosulfan, and ATG. Grafts were peripheral blood stem cells from unrelated donors (10/12 and 11/11 matched), that were manipulated by CD3/CD19 depletion and contained 20.3 and 28.2 × 10(6) CD34+ cells/kg body weight, respectively. Both patients achieved stable hematopoietic engraftment and stable donor chimerism. Neither acute or chronic graft-versus-host disease (GVHD) nor other severe transplant-related complications occurred. At a follow-up of 48 and 37 months, both patients are alive and well with normal levels of α-L-iduronidase and have made major neurodevelopmental progress. Treosulfan-based conditioning offers the advantage of reduced toxicity; the use of unrelated CD3/CD19-depleted peripheral stem cell grafts allows transfusion of high CD34+ cell numbers together with a "tailored" number of CD3+ cells as well as engraftment facilitating cells in order to achieve rapid hematopoietic engraftment while reducing the risk of graft rejection and GVHD. This regimen might be an additional option when unrelated donor HSCT is considered for a patient with MPS1-H
- 1 June 2011
- Vol. 48 (6) , 481-3
Numb chin syndrome in acute lymphoblastic leukemia.
Numb chin syndrome is a sensory neuropathy of the inferior alveolar branch of the trigeminal nerve, characterized by unilateral numbness of the chin, the lower lip and the buccal and gingival mucosa. We report a girl with acute lymphoblastic leukemia of B-cell type who initially presented with numb chin syndrome resulting from skull base infiltration.
- 1 June 2011
- Vol. 48 (6) , 481-3
Numb chin syndrome in acute lymphoblastic leukemia.
Numb chin syndrome is a sensory neuropathy of the inferior alveolar branch of the trigeminal nerve, characterized by unilateral numbness of the chin, the lower lip and the buccal and gingival mucosa. We report a girl with acute lymphoblastic leukemia of B-cell type who initially presented with numb chin syndrome resulting from skull base infiltration.
- 1 January 2008
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 46 (5) , 487-490
Effective management of pulmonary aspergillosis invading the thoracic spine in a child with high risk ALL requiring allogeneic bone marrow transplantation
Due to unacceptably high mortality, invasive fungal infections (IFI) have long been considered a contraindication against allogeneic stem cell transplantation. Despite severe immunosuppression an 11-year-old girl requiring allogeneic bone marrow transplant (BMT) for relapsed acute lymphoblastic leukemia was cured of a concurrent invasive pulmonary aspergillosis. Treatment comprised combinations of liposomal amphotericin B, caspofungin and voriconazole with donor granulocyte transfusions. This therapeutic regimen, including the choice of reduced intensity conditioning (RIC), allowed the patient to receive an allogeneic BMT. In hematological remission the child later developed fatal chronic graft-versus-host disease. Combined antifungal treatment and granulocyte support allow for effective management of IFI even in allogeneic stem cell transplant recipients. However, short-term benefits of RIC may be outweighed by late complications.
- 1 January 2008
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 46 (5) , 487-490
Effective management of pulmonary aspergillosis invading the thoracic spine in a child with high risk ALL requiring allogeneic bone marrow transplantation
Due to unacceptably high mortality, invasive fungal infections (IFI) have long been considered a contraindication against allogeneic stem cell transplantation. Despite severe immunosuppression an 11-year-old girl requiring allogeneic bone marrow transplant (BMT) for relapsed acute lymphoblastic leukemia was cured of a concurrent invasive pulmonary aspergillosis. Treatment comprised combinations of liposomal amphotericin B, caspofungin and voriconazole with donor granulocyte transfusions. This therapeutic regimen, including the choice of reduced intensity conditioning (RIC), allowed the patient to receive an allogeneic BMT. In hematological remission the child later developed fatal chronic graft-versus-host disease. Combined antifungal treatment and granulocyte support allow for effective management of IFI even in allogeneic stem cell transplant recipients. However, short-term benefits of RIC may be outweighed by late complications.
- 31 March 2007
- Published by Wiley in Pediatric Transplantation
- Vol. 11 (3) , 332-335
Durable remission following a third allogeneic stem cell transplantation in a patient with repeatedly relapsing SAA. The importance of stroma cells for sustained engraftment?
Diagnosis of acquired AATP which finally progressed to SAA was established in an eight-yr-old boy. PBSCT from an HLA-identical unrelated donor using high numbers of CD34+ selected stem cells was performed and resulted in complete remission for almost two yr. However, SAA reoccurred with 100% donor hematopoiesis and was reversed by a second CD 34+ selected PBSCT from the same donor. Declining blood cell counts after an interval of two yr indicated second relapse. Chimerism analysis in PB and BM aspirates revealed a small autologous cell population of 4-12% and 2-11%, respectively. Finally, a third transplantation with unmanipulated BM from the same donor resulted in sustained remission with 100% donor hematopoiesis. The patient is in complete remission for more than five yr following the third SCT. Late graft failure or late graft rejection known to occur after transplantation of highly purified CD34+ cells, or even graft exhaustion caused by stromal dysfunction due to the underlying disease necessitated a third transplantation. Regardless of the cause of relapse, transplantation of unmanipulated BM instead of highly purified PBSCTs led to a permanent and stable engraftment in a third attempt after two previous PBSCTs.
- 31 March 2007
- Published by Wiley in Pediatric Transplantation
- Vol. 11 (3) , 332-335
Durable remission following a third allogeneic stem cell transplantation in a patient with repeatedly relapsing SAA. The importance of stroma cells for sustained engraftment?
Diagnosis of acquired AATP which finally progressed to SAA was established in an eight-yr-old boy. PBSCT from an HLA-identical unrelated donor using high numbers of CD34+ selected stem cells was performed and resulted in complete remission for almost two yr. However, SAA reoccurred with 100% donor hematopoiesis and was reversed by a second CD 34+ selected PBSCT from the same donor. Declining blood cell counts after an interval of two yr indicated second relapse. Chimerism analysis in PB and BM aspirates revealed a small autologous cell population of 4-12% and 2-11%, respectively. Finally, a third transplantation with unmanipulated BM from the same donor resulted in sustained remission with 100% donor hematopoiesis. The patient is in complete remission for more than five yr following the third SCT. Late graft failure or late graft rejection known to occur after transplantation of highly purified CD34+ cells, or even graft exhaustion caused by stromal dysfunction due to the underlying disease necessitated a third transplantation. Regardless of the cause of relapse, transplantation of unmanipulated BM instead of highly purified PBSCTs led to a permanent and stable engraftment in a third attempt after two previous PBSCTs.